BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22270205)

  • 1. Comparison of four botulinum neurotoxin type A preparations in the treatment of hyperdynamic forehead lines in men: a pilot study.
    Oliveira de Morais O; Matos Reis-Filho E; Vilela Pereira L; Martins Gomes C; Alves G
    J Drugs Dermatol; 2012 Feb; 11(2):216-9. PubMed ID: 22270205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.
    Hexsel D; Brum C; do Prado DZ; Soirefmann M; Rotta FT; Dal'Forno T; Rodrigues TC
    J Am Acad Dermatol; 2012 Aug; 67(2):226-32. PubMed ID: 22041253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of forehead/glabellar rhytide complex with combination botulinum toxin a and hyaluronic acid versus botulinum toxin A injection alone: a split-face, rater-blinded, randomized control trial.
    Dubina M; Tung R; Bolotin D; Mahoney AM; Tayebi B; Sato M; Mulinari-Brenner F; Jones T; West DP; Poon E; Nodzenski M; Alam M
    J Cosmet Dermatol; 2013 Dec; 12(4):261-6. PubMed ID: 24305424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides.
    Carruthers A; Carruthers J; Cohen J
    Dermatol Surg; 2003 May; 29(5):461-7. PubMed ID: 12752512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing, efficacy and safety plus the use of computerized photography for botulinum toxins type A for upper facial lines.
    Lowe NJ; Shah A; Lowe PL; Patnaik R
    J Cosmet Laser Ther; 2010 Apr; 12(2):106-11. PubMed ID: 20151785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
    Hanke CW; Narins RS; Brandt F; Cohen JL; Donofrio LM; Downie J; Heinz M; Harrington L; McDaniel DH; Nestor M; Schlessinger J; Schlöbe A; Taub A; Weiss RA
    Dermatol Surg; 2013 Jun; 39(6):891-9. PubMed ID: 23506308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RimabotulinumtoxinB vs. onabotulinumtoxinA for the treatment of forehead lines: an evaluator-blind, randomized, pilot study.
    Lee DH; Kang SM; Feneran A; Youn CS; Kim JK; Cho S; Won CH; Chang SE; Lee MW; Choi JH; Moon KC
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e1-7. PubMed ID: 23030660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Baumann L; Brandt FS; Kane MA; Donofrio LM
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.
    Rzany B; Flynn TC; Schlöbe A; Heinz M; Harrington L
    Dermatol Surg; 2013 Jan; 39(1 Pt 1):95-103. PubMed ID: 23190342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
    Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
    Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of botulinum toxin type A and B for forehead rhytides: a randomized, double-blind, split-face study.
    Choi JW; Youn CS; An HT; Yoo JY; Na JI; Park KC; Youn SW; Huh CH
    J Dermatolog Treat; 2013 Apr; 24(2):126-32. PubMed ID: 21801115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines.
    Glogau R; Blitzer A; Brandt F; Kane M; Monheit GD; Waugh JM
    J Drugs Dermatol; 2012 Jan; 11(1):38-45. PubMed ID: 22206075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermal and epidermal remodeling using botulinum toxin type A for facial, non reducible, hyperkinetic lines: two case studies.
    Bowler PJ
    J Cosmet Dermatol; 2008 Sep; 7(3):241-4. PubMed ID: 18789065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
    Prager W; Rappl T
    J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial.
    Solish N; Rivers JK; Humphrey S; Muhn C; Somogyi C; Lei X; Bhogal M; Caulkins C
    Dermatol Surg; 2016 Mar; 42(3):410-9. PubMed ID: 26863598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part I: Upper facial wrinkles.
    Ascher B; Talarico S; Cassuto D; Escobar S; Hexsel D; Jaén P; Monheit GD; Rzany B; Viel M
    J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1278-84. PubMed ID: 20337830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of the ageing eyebrow and forehead: an objective dose-response study with botulinum toxin.
    Levy JL; Pons F; Jouve E
    J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):711-6. PubMed ID: 16836501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines.
    Cohen JL; Dayan SH; Cox SE; Yalamanchili R; Tardie G
    Dermatol Surg; 2012 Sep; 38(9):1497-505. PubMed ID: 22621180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
    Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
    J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.